Clinical trial
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease
NCT07901933 is registered in ClinicalTrials.gov with Cajal Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease
- Lead sponsor
- Cajal Therapeutics Inc.
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- November 30, 2027
- Enrollment
- 24 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
anemia, chronic kidney disease
Arms
As registered; 2 arms.
-
CTX001 plus oral iron
Participants receive CTX001 at the assigned cohort dose together with oral iron once daily for 29 days.
-
Placebo plus oral iron
Participants receive matching placebo together with oral iron once daily for 29 days.
Primary endpoints
Registered primary outcome measures; 6 primary.
-
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Number and percentage of participants with at least one (TEAE). An adverse event (AE) is any untoward medical occurrence in a participant, whether or not considered related to the study intervention. An AE is considered a treatment-emergent AE (TEAE) if the AE begins or worsens after the first dose of study intervention and on or before the last study visit.
-
Incidence of Serious TEAEs
Number and percentage of participants with at least one serious treatment-emergent adverse event (TEAE). A serious AE (SAE) is defined as any AE that, at any dose, meets one or more of the following criteria: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; results in a congenital anomaly or birth defect; or any important medical event that may jeopardize the participant or may require medical intervention to prevent one of the outcomes listed above.
-
Incidence of Clinically Significant Changes in Physical Examination
The investigator assesses the clinical significance of changes in physical examination findings.
-
Incidence of Clinically Significant Changes in Safety Laboratory Values
Safety laboratory evaluations include blood counts, serum chemistries, coagulation studies and urinalyses. Determination of clinical significance is based on investigator discretion.
-
Incidence of Clinically Significant Changes in Vital Signs
Vital signs include heart rate, respiratory rate, blood pressure, and temperature. Determination of clinical significance is based on investigator discretion.
+1 more primary endpoint
Lead sponsor's other trials
Cajal Therapeutics Inc., most recent start first.
Similar trials
Same condition (Anemia) and phase, most recent start first.
+88 more trials See the condition page